Phase 3 DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

Phase 3 DECISION Trial of Nexavar® (sorafenib) Meets Primary Endpoint of Improving Progression-Free Survival in Patients with Radioactive Iodine Refractory Differentiated Thyroid Cancer

[at noodls] – Wayne, NJ and South San Francisco, CA. – Jan. 03, 2013 Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial of Nexavar® (sorafenib) tablets in patients with … more

View todays social media effects on ONXX

View the latest stocks trending across Twitter. Click to view dashboard

See who ONYX is hiring next, click here to view

Share this post

Comments (0)